• Age ≥ 18 years at the time of screening

• Written informed consent obtained from the subject prior to performing any protocol-related procedures

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Weight ≥ 35 kg

• Must have a life expectancy of at least 24 months

• Complete surgical resection of T1-2N0M0 NSCLC or T3/T4 multifocal NSCLC

• Any pathologic subtype of NSCLC is eligible, including adenocarcinoma and squamous carcinoma. Patients with targetable genomic alterations without approved or available targeted adjuvant therapy options are eligible

• Patients with detectable plasma ctDNA before or after complete surgical resection are eligible (RaDaR TM assay, Inivata Morrisville, North Carolina, USA).

• No prior chemotherapy or radiotherapy is allowed for the current diagnosis of resected NSCLC.

⁃ Adequate organ and marrow function as defined in Table 4 (3.1.1)

⁃ Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening to 180 days after the final dose of study treatment. A serum pregnancy test within 72 hours prior to the initiation of therapy will be required for women of childbearing potential. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period

⁃ Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 180 days after receipt of the final dose of study treatment. It is strongly recommended for the female partner of a male subject to also use a highly effective method of contraception throughout this period. In addition, male subjects must refrain from sperm donation while on study and for 180 days after the final dose of study treatment.